Latest news with #Lantheus
Yahoo
14-05-2025
- Business
- Yahoo
Lantheus Holdings (NasdaqGM:LNTH) Adjusts 2025 Earnings Guidance
Lantheus Holdings recently adjusted its earnings guidance for 2025, reducing anticipated revenues, which has coincided with a 4% decline in its share price over the last quarter. In Q1 2025, the company reported a significant drop in net income and earnings per share, a factor that could influence investor sentiment negatively. Despite promising developments in product diagnostics, Lantheus's lowered guidance and governance changes may have added weight against broader market gains, as the market rose 4% in the same period. These factors underscore the complex environment the company is navigating as it addresses financial and operational challenges. We've discovered 2 warning signs for Lantheus Holdings that you should be aware of before investing here. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. The recent adjustment in Lantheus Holdings' earnings guidance for 2025 and the resulting 4% decline in its share price underscore the immediate challenges the company faces. On a broader horizon, Lantheus has delivered significant returns with a total shareholder return exceeding 500% over the past five years. This substantial gain highlights the potential resilience and growth capacity of the company despite recent setbacks. However, in the past year, Lantheus underperformed relative to both the US Medical Equipment industry, which returned 11%, and the broader US market's 11.6% gain. The revision in earnings guidance reflects potential implications for future revenue and earnings projections. Analysts anticipate revenue growth at 8.2% annually over three years, lower than the US market's 8.4%. Earnings, forecasted to grow 21.16% annually, hinge on the success of new market expansions and product launches. Despite the current share price of US$104.84 being below the consensus price target of US$129.31, it represents a discount, suggesting room for potential price appreciation based on future growth prospects. This context is crucial for investors assessing the current position and outlook of Lantheus within the market. Understand Lantheus Holdings' earnings outlook by examining our growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:LNTH. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
12-05-2025
- Health
- Yahoo
Weill Cornell receives grant to test new imaging approach for prostate cancer
Weill Cornell Medicine in the US has secured a grant of approximately $4m from the National Cancer Institute for a clinical trial to assess a new imaging approach in prostate cancer monitoring. The study will test whether the addition of prostate-specific membrane antigen (PSMA) - positron emission tomography (PET) computed tomography (CT) (PSMA-PET CT) imaging modality to active surveillance regimens improves prostate cancer monitoring. With a possible two-year extension, this five-year grant will investigate if this imaging modality can minimise the requirement for biopsies during active surveillance of this cancer and eliminate its presence that needs treatment. According to Weill Cornell Medicine, PSMA-PET CT leverages a radioactive diagnostic agent for identifying a protein present on the surface of prostate cells and at higher levels on prostate cancer cells. This imaging technique is said to have already been employed to identify metastasis in high-risk cases and to monitor remission. Under this approach, patients are monitored through regular prostate-specific antigen (PSA) level blood tests, magnetic resonance imaging (MRI) scans, and biopsies to check for any signs of cancer progression. The study's principal investigator, Dr Timothy McClure, along with colleagues from Weill Cornell Medicine's department of radiology and the department of pathology's molecular imaging and therapeutics division, will assess whether PSMA-PET CT addition can enhance the specificity and sensitivity of prostate cancer surveillance while minimising screening-related harm. Dr McClure said: 'Our trial leverages cross-sector collaboration to innovate and streamline care for patients with prostate cancer. 'We hope to develop alternatives for prostate cancer surveillance that help us more effectively stratify which patients need treatment.' Weill Cornell Medicine noted that 200 men with low-risk or intermediate-risk prostate cancer will be assigned by the researchers, and the trial will enrol subjects at NewYork-Presbyterian/Weill Cornell Medical Center and four additional sites. The study is also supported by Lantheus, the producer of the diagnostic agent used in PSMA-PET CT. The research is partly supported by the National Cancer Institute. Last month, Weill Cornell Medicine researchers and the New York Genome Center identified a method for cancer detection via blood test, using whole-genome sequencing and error correction. "Weill Cornell receives grant to test new imaging approach for prostate cancer" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
09-05-2025
- Business
- Yahoo
Lantheus price target lowered to $120 from $134 at JonesResearch
JonesResearch lowered the firm's price target on Lantheus (LNTH) to $120 from $134 and keeps a Buy rating on the shares following the Q1 report. With Pylarify facing competitive pressure and its net sales down 0.5% year-over- year, an ongoing business reorganization and reduced fiscal 2025 earnings guidance, the stock has faced significant negative pressure, the analyst tells investors in a research note. The firm acknowledges near-term concerns over emerging PSMA-PET competition and potential increased operating expenses arising from recent acquisitions, but continues to have confidence in the medium- to long-term potential of Lantheus' radiopharmaceutical pipeline. It expects strong execution and improved margins following the completion of acquisitions and divestitures. Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on LNTH: Disclaimer & DisclosureReport an Issue Lantheus: Strategic Growth Potential and Market Positioning Justify Buy Rating Despite Challenges Lantheus Holdings Reports Q1 2025 Financial Results Lantheus Holdings Earnings Call: Mixed Outlook Amid Strategic Moves Balancing Challenges and Opportunities: Justin Walsh's Optimistic Buy Rating for Lantheus Holdings Amidst Strategic Reorganization Strategic Growth and Focus: Lantheus's Positive Long-Term Outlook Justifies Buy Rating Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
07-05-2025
- Business
- Business Wire
Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights
LOS ANGELES--(BUSINESS WIRE)-- The DJS Law Group announces that it is investigating claims on behalf of investors of Lantheus Holdings, Inc. ('Lantheus' or 'the Company') (NASDAQ: LNTH) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Lantheus reported its financial results for the first quarter of 2025 on May 7, 2025. Along with the Company's flat sales for the quarter, it also significantly cut its full-year earnings estimate. Based on this news, shares of Lantheus fell by more than 24.3% in intraday trading. If you are a shareholder who suffered a loss, contact us to participate. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
07-05-2025
- Business
- Yahoo
Why Lantheus (LNTH) Shares Are Getting Obliterated Today
What Happened? Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) fell 22.2% in the afternoon session after the company reported weak first quarter 2025 results which included a significant miss on full-year EPS guidance and EPS falling short of Wall Street's estimates. Sales were flat, with a slight drop in PYLARIFY mostly offset by small gains in other parts of the business. Operating profit also fell. The real issue was the cut to full-year earnings, now seen at $6.60 to $6.70 per share, well below the $7.00 to $7.20 range it gave before. Overall, this was a softer quarter. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Lantheus? Access our full analysis report here, it's free. What The Market Is Telling Us Lantheus's shares are somewhat volatile and have had 13 moves greater than 5% over the last year. But moves this big are rare even for Lantheus and indicate this news significantly impacted the market's perception of the business. Lantheus is down 6.4% since the beginning of the year, and at $83.08 per share, it is trading 32.8% below its 52-week high of $123.62 from July 2024. Investors who bought $1,000 worth of Lantheus's shares 5 years ago would now be looking at an investment worth $6,475. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
